Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
The interferon- and ribavirin- (RBV) free combination regimen of glecaprevir plus pibrentasvir (GLE/PIB) for the treatment of genotypes 1 to 6 of chronic hepatitis C (CHC) viral infection has been shown to be safe and effective in randomized controlled clinical trials.
This observational study is an effectiveness research examining the regimen of GLE/PIB, used according to local label, under real world conditions in a clinical practice patient population.
Inclusion Criteria:
Exclusion Criteria:
None.
Epagny Metz Tessy, Haute-Savoie 74370, France
Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54511, France
Kifissia, Attica 14564, Greece
Nea Efkarpia, Thessaloniki 54603, Greece
Athens, 10676, Greece
Pireaus, 18454, Greece
GUSH DAN, 7565016, Israel
Modena, Emilia-Romagna 41124, Italy
Krakow, Lesser Poland Voivodeship 31-202, Poland
Wałbrzych, Lower Silesian Voivodeship 58-300, Poland
Zielona GORA, Lower Silesian Voivodeship 65-191, Poland
Bialystok, Podlaskie Voivodeship 15-276, Poland
Barreiro, Lisbon District 2834-003, Portugal
Vila Nova de Gaia, Porto District 4434-502, Portugal
Lisbon, 1069-166, Portugal
Lisbon, 1649-035, Portugal